Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co(II) and Zn(II) compounds.
BACKGROUND
Despite continuous efforts, the treatment of canine cancer has still to deliver effective strategies. For example, traditional chemotherapy with doxorubicin and/or docetaxel does not significantly increase survival in dogs with canine mammary tumors (CMTs).


OBJECTIVE
Evaluate the efficiency of two metal compounds [Zn(DION)2]Cl (TS262, DION = 1,10-phenanthroline-5,6-dione) and [CoCl(H2O)(DION)2][BF4] (TS265) and novel nanovectorizations designed to improve the anti-cancer efficacy of these compounds in a new CMT derived cell line (FR37-CMT).


METHODS
FR37-CMT cells were exposed to different concentrations of TS262 and TS265 and two new nanoparticle systems and cellular viability was determined. These nanosystems are composed of polyethylene-glycol, bovine-serum-albumin and TS262 or TS265 (NanoTS262 or NanoTS265, respectively).


RESULTS
In FR37-CMT, TS262 and TS265 displayed IC50 values well below those displayed by doxorubicin and cisplatin. The nanovectorizations further decreased the IC50 values.


CONCLUSIONS
TS262 and TS265 proved to be effective against FR37-CMT cells and more effective than of doxorubicin and cisplatin. The Nanosystems efficiently delivered the cytotoxic cargo inducing a significant reduction of cell viability in FR37-CMT cell line when compared to the free compounds.


CONCLUSIONS
TS262 and TS265 are compounds with potential in the treatment of CMTs. NanoTS262 and NanoTS265 demonstrate that such simple nanovectorization via gold nanoparticles shows tremendous potential as anti-cancer formulations, which may easily be expanded to suit other cargo.
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Caparica, Portugal.|CQE, Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
L R
http://orcid.org/0000-0002-8637-346X
LR
Raposo
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Caparica, Portugal.
C
C
Roma-Rodrigues
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Caparica, Portugal.
J
J
Jesus
CQE, Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.|Área Departamental de Engenharia Química, Instituto Superior de Engenharia de Lisboa, Lisboa, Portugal.
L M D R S
LMDRS
Martins
CQE, Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
A J
AJ
Pombeiro
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Caparica, Portugal.
P V
PV
Baptista
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Caparica, Portugal.|CQE, Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
A R
AR
Fernandes
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003035:Cobalt / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006046:Gold / Q000627:therapeutic use*; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy*; D053768:Metal Nanoparticles / Q000627:therapeutic use*; D017967:Zinc Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D017967:Zinc Compounds; D003035:Cobalt; D006046:Gold

FR37-CMT
; 1,10-phenanthroline-5,6-dione metal compounds; canine mammary tumours; cisplatin; doxorubicin; gold nanoparticles; nanotechnology